At a glance
A global or EU eCTD is a strong starting point, but it is not proof of Swissmedic readiness. First define the product, application type and Swiss route. Then verify technical eCTD validity, a complete Swiss Module 1, consistent Modules 2 to 5, Swiss product information and packaging, manufacturing and GMP evidence, safety handoffs, and every change since the reference decision. A useful gap review identifies each missing item, its owner, supporting evidence and effect on the planned submission.
Key takeaways
- Choose the Swiss application type and route before applying a generic dossier checklist.
- Treat eCTD as a controlled lifecycle, not a folder of current documents.
- Reconcile Swiss Module 1, product texts and reference-authority records with Modules 2 to 5.
- Assign every gap to an owner, evidence item and filing decision.
What must be fixed before the dossier review starts?
Start with a one-page dossier basis: medicinal product and presentation, active substance, application type, intended indication, orphan or special status if relevant, legal applicant, proposed Swiss holder, current authorisations and the intended Swiss procedure. This is a planning record, not a Swissmedic form. It prevents a false universal checklist because the required documents depend on product class, application type and route. Confirm early whether the applicant can satisfy Article 10 of the Therapeutic Products Act and whether the scientific, quality and administrative scope describe the same product.
Is the eCTD technically and historically usable?
Swissmedic describes eCTD as a five-module electronic format for managing both a dossier and its lifecycle. Module 1 is Swiss-specific, while Modules 2 to 5 are internationally harmonised. Readiness therefore includes technical validation against the current Swiss specification and validation criteria, a continuous and intelligible sequence history, correct leaf lifecycle operations and access to all prior sequences. A technically valid new sequence cannot repair an unexplained missing baseline, conflicting metadata or a lifecycle that the future Swiss holder cannot control after authorisation.
Where should a module-by-module gap review look?
Review the dossier by question, not merely by document count. Module 1 should prove the Swiss application, parties, declarations, forms, product information and route-specific evidence. Modules 2 to 5 should support one consistent indication, posology, manufacturing chain, control strategy, nonclinical position and clinical benefit-risk case. The table is our working gap map rather than an authority checklist. Record each gap, the source record that resolves it, the owner and whether it changes the route, submission scope or product text.
| Module | Readiness check | Evidence and owner | Decision if a gap remains |
|---|---|---|---|
| Module 1 | Swiss forms, applicant, route, declarations, product information and annexes agree | Controlled Swiss administrative index; regulatory owner | Correct before filing or confirm the route-specific exception |
| Module 2 | Summaries match the proposed Swiss indication and current underlying data | Approved summary set and reconciliation record; regulatory and subject leads | Update summaries or revise the proposed scope |
| Module 3 | Sites, process, controls, specifications and stability describe the same commercial product | Site and change matrix, GMP evidence; quality owner | Resolve discrepancy and assess reference-route comparability |
| Module 4 | Nonclinical package and summaries support the application type and known changes | Study inventory and assessment history; nonclinical owner | Provide justification, literature or required reports |
| Module 5 | Clinical evidence, safety updates and benefit-risk support the exact Swiss claim | Study and authority-decision map; clinical and safety owners | Narrow, justify or supplement the requested claim |
What belongs in the Swiss administrative and product-information package?
The formal package needs the current Swiss forms, signatures, administrative evidence and route-specific annexes in the required structure. Product information is a regulated deliverable, not a late translation task: the professional information is prepared in German, French and Italian, and the authorisation holder is responsible for the translations; patient information and packaging must follow the applicable Swiss rules and approved wording. Reconcile names, strengths, pharmaceutical form, indications, warnings, storage, holder and manufacturer details across the forms, texts, mock-ups and quality dossier. Translation governance should include medical review, version control and documented resolution of language differences.
What does an Article 13 reference package need to show?
For an Article 13 application, provide the complete documentation in CTD format plus the current final decision and assessment report from the selected reference authority, the reference country’s Module 1 and the Swiss Module 1. Swissmedic’s guidance requires the applicant to show that the foreign and Swiss products and documentation are comparable and to disclose later changes and relevant divergent, negative, withdrawn or suspended decisions. Article 13 allows Swissmedic to consider foreign assessment results; it does not convert the foreign authorisation automatically or remove Swiss-specific requirements.
Sources and further reading: [5]
How should quality, GMP and safety handoffs be evidenced?
Quality readiness connects the dossier to real sites and operations. Reconcile every manufacturer, testing site, batch-release step, specification and manufacturing change across Module 3, application forms and reference-authority records. Verify current GMP or establishment evidence and the intended Swiss importer and release model rather than assuming a foreign licence covers Swiss activities. Safety readiness also needs a handoff: the developing or global safety system must supply the future Swiss holder and responsible PV person with the product history, risk-management commitments, safety variations and data needed from the application stage onward.
Which failure modes should stop submission readiness?
Stop and investigate if the product identity differs between modules, the sequence history is incomplete, the reference decision is outdated, open foreign variations are absent, manufacturers do not match, translations change medical meaning, or no one can identify the controlled source for the Swiss text. A pre-submission package should contain the agreed basis, route rationale, module gap log, document index, lifecycle map, reference-decision chronology, text reconciliation, site and GMP matrix, safety handoff and signed ownership plan. These are suggested planning controls, not a substitute for product-specific Swiss regulatory advice.
- Do not file with an unresolved product or manufacturer identity conflict.
- Do not infer a Swiss route solely from the existence of an EU or other foreign authorisation.
- Do not translate uncontrolled or superseded source text.
- Do not hand over an eCTD without usable sequence history and future access.
MAH / CH
Swiss dossier-readiness worksheet
Use this planning checklist to prepare a focused review without sending confidential dossier content.
- Frozen product, application type, indication and Swiss route hypothesis
- Eligible Swiss applicant and proposed authorisation holder
- Technically validated eCTD with complete accessible sequence history
- Swiss Module 1 forms, declarations and route evidence
- Reconciled product information, packaging and translation sources
- Reference decision, assessment report and post-decision change chronology
- Manufacturer, testing site, GMP and supply-chain consistency matrix
- Named owners for quality, clinical, safety and lifecycle gap closure
Continue exploring
Regulatory affairsQuestions before your next step
Can an EU eCTD be reused for Swissmedic?
Yes, much of the scientific content can be reused when it is current and matches the Swiss application. Swiss Module 1, Swiss product information, route-specific records and lifecycle reconciliation still need dedicated work.
Is eCTD readiness only a technical validation question?
No. Technical validation is necessary, but readiness also means an intelligible lifecycle, complete prior sequences, internally consistent content and the future holder’s ability to maintain the dossier.
Must all dossier content be translated into Swiss languages?
No. Translation needs depend on the document and current submission rules. Swiss product information and packaging have specific language requirements, while scientific dossier content is governed by the applicable Swissmedic guidance.
What must be added for an Article 13 application?
The package depends on the case, but current guidance calls for the complete CTD, Swiss and reference-country Module 1 material, final decision and assessment report, plus evidence of comparability and later lifecycle changes.
When should a dossier gap review happen?
Run an initial review before committing to the route and filing plan, then close and recheck gaps against the final submission baseline. Repeat targeted review after major reference-authority or manufacturing changes.
Sources and further reading
- Swissmedic: eCTD submissions
- Swissmedic: Formal requirements for authorisation applications
- Swissmedic: Product information for human medicinal products
- Swissmedic: Information on packaging
- Swissmedic: Authorisation under Article 13 TPA
- Swissmedic: SwissGMDP database
- Swiss Confederation: Therapeutic Products Act, SR 812.21
- Swissmedic: Requirements of the Responsible Person for Pharmacovigilance
Independent editorial information for business planning. This is not regulatory or legal advice. Current official guidance prevails; any external specialist introduction is discussed with you first. Please do not send patient data or confidential dossiers.
Free first review
Identify the next Swiss dossier-readiness decision
Send a non-confidential summary of your company, product stage and specific question. We review your enquiry and discuss any specialist introduction with you first.
